MAP2K7 and thyroid gland carcinoma: Song et al. demonstrated that the effect of vemurafenib treatment was transient and followed by reactivation of the phosphorylation of ERK; however, a combination strategy with a MEK inhibitor overcame the limitations of a transient vemurafenib response in BRAF-mutated thyroid cancers 62.